Raut Sanket B, Canales Juan J, Ravindran Manoj, Eri Rajaraman, Benedek David M, Ursano Robert J, Johnson Luke R
Schools of Psychological Sciences, College of Health and Medicine, University of Tasmania, TAS, 7250, Australia.
Department of Psychiatry, North West Private Hospital, Burnie, TAS, Australia.
J Psychiatr Res. 2022 Jun;150:246-256. doi: 10.1016/j.jpsychires.2022.03.045. Epub 2022 Apr 4.
Post-traumatic stress disorder (PTSD) develops after an exposure to a life-threatening event and is characterized by intrusive memories. According to memory reconsolidation theory retrieval of memory under certain conditions leads to its labilization and subsequent re-storage which could be disrupted by drugs. Propranolol has been the most commonly investigated drug for memory reconsolidation therapy in clinical trials. Intervention with propranolol have shown mixed results in PTSD patients with some studies showing improvement in symptoms while other failing to replicate these findings. We conducted a systematic review and meta-analysis to determine the efficacy of trauma memory disruption by propranolol on PTSD symptoms and physiological responses in PTSD patients. 3224 publications were assessed for eligibility. Seven studies on effects of propranolol on PTSD symptoms and 3 studies on effects of propranolol on physiological responses were incorporated in the meta-analyses. Overall, results indicate that propranolol did not show a beneficial effect on PTSD symptoms (standardized mean difference: 1.29; 95% CI = -2.16 - 0.17). Similarly, propranolol did not influence skin conductance (standardized mean difference: 0.77; 95% CI = -1.85 - 0.31) or EMG response (standardized mean difference: 0.16; 95% CI = -0.65 - 0.33). However, propranolol significantly reduced heart rate after trauma memory recall compared to placebo (standardized mean difference: 0.67; 95% CI = -1.27 to -0.07). This study finds a lack of evidence for the efficacy of propranolol on traumatic memory disruption, in PTSD patients, to recommend its routine clinical use. However, a high level of heterogeneity, variation in propranolol dosage and inadequate sample sizes mean that these findings require cautious interpretation.
创伤后应激障碍(PTSD)在经历危及生命的事件后发生,其特征为侵入性记忆。根据记忆再巩固理论,在某些条件下对记忆的提取会导致其不稳定,随后重新存储,而这一过程可能会被药物打断。普萘洛尔是临床试验中用于记忆再巩固治疗研究最广泛的药物。对PTSD患者使用普萘洛尔进行干预的结果喜忧参半,一些研究显示症状有所改善,而其他研究则未能重复这些发现。我们进行了一项系统综述和荟萃分析,以确定普萘洛尔对创伤记忆的干扰对PTSD患者PTSD症状和生理反应的疗效。评估了3224篇出版物的 eligibility。七项关于普萘洛尔对PTSD症状影响的研究和三项关于普萘洛尔对生理反应影响的研究纳入了荟萃分析。总体而言,结果表明普萘洛尔对PTSD症状没有显示出有益效果(标准化均值差:1.29;95%CI = -2.16 - 0.17)。同样,普萘洛尔对皮肤电导率没有影响(标准化均值差:0.77;95%CI = -1.85 - 0.31)或肌电图反应(标准化均值差:0.16;95%CI = -0.65 - 0.33)。然而,与安慰剂相比,普萘洛尔在创伤记忆回忆后显著降低了心率(标准化均值差:0.67;95%CI = -1.27至-0.07)。本研究发现,缺乏证据表明普萘洛尔对PTSD患者的创伤记忆干扰有效,从而推荐其常规临床使用。然而,高度的异质性、普萘洛尔剂量的变化和样本量不足意味着这些发现需要谨慎解读。